DNA Repair Gene Associated with Clinical Outcome of Epithelial Ovarian Cancer Treated with Platinum-based Chemotherapy |
Kang, Shan
(Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital)
Sun, Hai-Yan (Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital) Zhou, Rong-Miao (Department of Molecular Biology, Hebei Medical University, Fourth Hospital) Wang, Na (Department of Molecular Biology, Hebei Medical University, Fourth Hospital) Hu, Pei (Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital) Li, Yan (Department of Molecular Biology, Hebei Medical University, Fourth Hospital) |
1 | Azuma K, Komohara Y, Sasada T, et al (2007). Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci, 98, 1336-43. DOI ScienceOn |
2 | Cao ZY (2004) Chinese Obstetrics and Gynecology. Bejing Publisher, pp 2153. |
3 | du Bois A, Quinn M, Thigpen T, et al (2005). 2004 consensus statements on the management of ovarian cancer, Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol, 16, viii7-12. DOI ScienceOn |
4 | Fleming ND, Agadjanian H, Nassanian H, et al (2012). Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer, 118, 689-97. DOI ScienceOn |
5 | Giachino DF, Ghio P, Regazzoni S, et al (2007). Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res, 13, 2876-81. DOI ScienceOn |
6 | Ji g, Lin Y, Cao SY, et al (2012). XPC939A>C and 499C>T polymorphisms and skin cancer risk, a meta-analysis. Asian Pac J Cancer Prev, 13, 4983-8. DOI ScienceOn |
7 | Kalikali A, Kanaki M, Vassalou H, et al (2009). DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer, 10, 118-23. DOI ScienceOn |
8 | Khan SG, Metter EJ, Tarone RE, et al (2000). A new xeroderma pigmentosum group C poly (AT) insertion/deletion polymorphism. Carcinogenesis, 21, 1821-5. DOI |
9 | Khan SG, Munize-Medina V, Shahlavi T, et al (2002). The human XPC DNA repair gene, arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function. Nucleic Acids Res, 30, 3624-31. DOI ScienceOn |
10 | Kim HS, Kim MK, Chuang HH, et al (2009). Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds, a Korean population-based study. Gynecol Oncol, 113, 264-9. DOI ScienceOn |
11 | Lindahl T, Wood RD (1999). Qualityc control by DNA repair. Science, 286, 1897-905. DOI ScienceOn |
12 | Masutani C, Sugasawa K, Yanagisawa J, et al (1994). Purification and cloning of a nucleotide excision repair complex involving the xeroderma pigmentosum group C protein and a human homologue of yeast RAD23. EMBO J, 13, 1831-43. |
13 | Reed E (1998). Platinum-DNA adduct, nucleotide excision repair and platinumbased anticancer chemotherapy. Cancer Treat Rev, 24, 331-44. DOI ScienceOn |
14 | Miller SA, Dybes DD, Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Re, 16, 1215. DOI ScienceOn |
15 | Park DJ, Stoehlmacher J, Zhang W, et al (2001). A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res, 61, 8654-58. |
16 | Qiu L, Wang Z, Shi X and Wang Z (2008). Associations between XPC polymorphisms and risk of cancers, A meta-analysis. Eur J Cancer, 44, 2241-53. DOI ScienceOn |
17 | Rosell R, Taron M, Barnadas A, et al (2003). Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control, 10, 297-305. |
18 | Saldivar JS, Lu KH, Liang D, et al (2007). Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol, 107, S223-9. DOI ScienceOn |
19 | Sun X, Li F, Sun N, et al (2009). Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer, 65, 230-6. DOI ScienceOn |
20 | Walsh CS, Ogawa S, Karahashi H, et al (2008). ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol, 26, 2952-8. DOI ScienceOn |
21 | Weaver DA, Crawford EL, Warner KA, et al (2005). ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer, 4, 18. DOI ScienceOn |
22 | Zamble DB, Lippard SJ (1995). Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci, 20, 435-9. DOI ScienceOn |
23 | Yu D, Zhang X, Liu J, et al (2008). Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res, 14, 2878-86. DOI ScienceOn |
24 | Yuan P, Miao XP, Zhang XM, et al (2005). Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Zhonghua Yi Xue Za Zhi, 85, 972-5. |